1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Aprogen, Inc

Aprogen, Inc

KKRX:007460
1,900.00
KRW
-20.00
(-1.04%)
-8,713.89EPS
52.60BMarket Cap
Aprogen, Inc
KRX:007460
(Korea Stock Exchange)

Recent

price

1,900.00

P/E

ratio

- -

div

yld

-NaN%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
2,637,847.09
4,021,403.42
1,607,475.03
518,655.89
329,917.81
251,783.23
150,573.28
90,751.42
45,183.47
25,646.59
33,697.01
6,811.35
5,838.53
9,579.03
8,718.78
5,945.94
8,730.46
Revenue per Share
-154,826.04
-596,296.49
-113,705.16
-257,355.01
53,647.35
12,950.94
6,610.37
5,261.32
-28,420.1
-3,552.51
-12,321.37
-24,327.97
-7,351.82
-3,538.23
-3,373.31
-3,538.23
-5,250.26
Basic EPS, GAAP
-65,991.78
-60,160.4
141,185.58
-32,263.21
73,154.7
-417.74
3,848.21
17,972.31
-4,893.35
-3,045.71
5,145.05
-30,981.32
-10,306.78
-7,191.05
-3,957.39
-3,268.99
-5,638.4
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
1,170,609.81
363,900.21
313,299.71
16,642.88
70,598.96
86,923.1
93,833
135,120.01
95,667.78
78,874.28
78,406.2
488.44
13,844.42
9,078.58
8,393.1
7,692.42
2,877.75
Book Value per Share
1,152,210.79
351,503.39
309,114.96
15,352.96
69,394.68
85,761.22
92,737.02
134,232.17
95,623.11
77,808.95
77,461.76
-106.11
12,980.7
6,491.71
5,604.46
1,725.85
-2,733.29
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
1
3
4
4
13
16
17
20
16
Basic Weighted Avg Shares
232,257
354,366
170,688
103,040
76,535
65,932
54,836
40,376
51,047
78,249
127,143
26,296
78,349
150,578
150,114
117,974
138,901
Sales/Revenue/Turnover
4.51
-6.11
14.06
4.28
11.24
9.12
9.24
8.71
3.08
3.28
3.12
-359.89
-145.95
-59.02
-57.83
-81.01
-66.42
Operating Margin (%)
6,193
16,416
19,488
2,482
2,358
2,300
2,336
2,226
2,033
3,251
4,308
25,262
28,392
29,071
24,305
23,597
23,261
Depreciation Expense
-13,632
-52,546
-12,074
-51,128
12,445
3,391
2,407
2,341
-32,108
-10,839
-46,490
-93,920
-98,657
-55,619
-58,079
-70,202
-83,531
Net Income, GAAP
- -
- -
4.03
- -
- -
- -
27.53
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-5.87
-14.83
-7.07
-49.62
16.26
5.14
4.39
5.8
-62.9
-13.85
-36.57
-357.17
-125.92
-36.94
-38.69
-59.51
-60.14
Profit Margin (%)
462
-75,216
-58,631
-39,201
-39,591
-23,530
-18,496
159,941
41,509
238,448
349,410
-318,829
121,644
18,567
21,357
-5,126
-32,226
Working Capital
69,342
33,017
14,920
18,942
- -
667
333
50,214
92,570
8,152
26,661
50,971
31,822
32,288
32,327
40,718
36,642
LT Debt
103,282
645
-7,286
3,858
16,365
30,860
35,317
149,556
195,512
517,536
690,040
-806
461,002
417,688
440,091
458,610
414,246
Total Equity
- -
- -
17.98
- -
11.92
9.42
5.53
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
12.72
- -
25.91
10.75
5.31
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-12.38
-77.69
-33.48
-233.13
123.08
14.36
7.28
2.53
-18.61
-4.66
-15.8
-58.49
-90.82
-30.65
-37.91
-44.3
-82.23
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
147,144
148,442
144,803
LT Borrowings
40,000
38,000
36,000
LT Finance Leases
718
652
642
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
21
21
21
Market Capitalization
215,164
96,006
52,597

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
178,643
166,517
162,672
Cash, Cash Equivalents & STI
50,760
40,462
43,163
Accounts Receivable, Net
25,976
27,083
24,654
Inventories
60,894
65,604
54,253
Total Current Liabilities
183,769
196,506
194,898
Payables & Accruals
- -
- -
- -
ST Debt
147,144
148,442
144,803
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-5,679.82%
-11,472.97%
4.21%
Free Cash Flow
-208.39%
-152.66%
-4.81%
Net Income, GAAP
-115.21%
17.75%
20.87%
Sales/Revenue/Turnover
28.81%
37.82%
-21.41%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
38,081
35,592
36,793
39,648
150,114
2025
26,727
23,235
35,554
31,529
117,974
2026
36,292
35,526
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1,829.09
-164.92
-1,544.23
79.81
-3,373.31
2025
-766.68
-11,799.1
-1,113.59
-863.44
-3,538.23
2026
-13,016.44
-1,182
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Aprogen Medicines Inc. designs, manufactures, and maintains plant facilities for steelwork, petrochemistry, shipbuilding, power plant, and LNG base industries in South Korea; offers thermal and cold spray services, clad rolls, clad plates, wear plates, clad pipes and fittings, and plasma transferred arcs; provides the Nukon system, a special heat-preservation solution for pressurized water reactor power plant containment buildings, foamglas cellular glass insulation products, and fireproof insulation works for POSCO furnaces and boilers. The company, founded in 1971 and headquartered in Seongnam-si, Gyeonggi-do, operates primarily within the industrials sector, serving heavy industry clients across domestic markets. Formerly known as Aprogen KIC Inc., it changed its name to Aprogen Medicines Inc. in April 2021 to reflect strategic evolution; completed the acquisition of remaining shares in Aprogen Inc. in July 2022 through a merger; and agreed in May 2025 to acquire an additional 20.06% stake in AP Healthcare Inc. from Aprogen Biologics Inc. for KRW 58.4 billion, with completion expected by August 2025.